Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients

Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma

(2013) Christoph Tinchon et al.   ACTA ONCOLOGICA

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer

(2013) M Stotz et al.   BRITISH JOURNAL OF CANCER

A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients

(2013) G Absenger et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The value of C-reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma

(2012) Tomoki Nakamura et al.   EUROPEAN JOURNAL OF CANCER

Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer

(2012) De-shen Wang et al.   MEDICAL ONCOLOGY

An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study

(2011) M J Proctor et al.   BRITISH JOURNAL OF CANCER

Preoperative Neutrophil-to-Lymphocyte Ratio (NLR) is Associated with Reduced Disease-free Survival Following Curative Resection of Pancreatic Adenocarcinoma

(2011) G. Garcea et al.   WORLD JOURNAL OF SURGERY

Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas

(2009) J.K. Pine et al.   EJSO

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE